Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 9, 2026

Stock market today: Dow, S&P 500, Nasdaq rebound to extend winning streak, oil rises ahead of US-Iran talks

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq rebound to extend winning streak, oil rises ahead of US-Iran talks US stocks reversed earlier losses on Thursday after Israel's Prime Minister Benjamin Netanyahu agreed to direct negotiations with Lebanon, which was seen as supportive of the fragile ceasefire deal the US struck…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Israel's strikes in Lebanon represent a clear violation of the ceasefire agreement

    60% confidence

  • Brent crude is set to average more than $100 a barrel through 2026 if the Strait of Hormuz remains closed for another month

    60% confidence

  • President Trump was very optimistic about a peace deal with Iran ahead of talks scheduled for the weekend

    60% confidence

  • Israel's military killed more than 200 Hezbollah militants on Wednesday

    60% confidence

  • The most probable situation is that Satoshi is somebody who's not talking to documentary film crews, investigative journalists, and not participating in forums and conferences with his real name

    60% confidence

  • As there's no new data, nobody's found anything conclusive about Satoshi Nakamoto's identity

    60% confidence

  • There is no ceasefire in Lebanon

    60% confidence

  • The US-Iran framework deal for negotiation has been openly and clearly violated, making ceasefire or negotiations unreasonable

    60% confidence

  • The situation remains fluid and we continue to see the risks to our price forecast as skewed to the upside

    60% confidence

  • Under base-case outlook, flows through the strait will start picking up this weekend, followed by gradual one-month recovery in Persian Gulf exports to pre-war levels, with Brent averaging $82 in Q3 and $80 in Q4

    60% confidence

  • Anthropic is eating Palantir's lunch

    60% confidence

  • If the US doesn't see the Strait of Hormuz beginning to reopen, the White House is not going to abide by our terms if the Iranians are not abiding by their terms

    60% confidence

  • Netanyahu instructed the Cabinet to open direct negotiations with Lebanon as soon as possible

    60% confidence

Data points we hold from this source

S&P 500 · daily return0.62 percent
Dow Jones Industrial Average · year to date return0.3 percent
Dow Jones Industrial Average · daily return0.58 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500, Nasdaq rebound to extend winning streak, oil rises ahead of US-Iran talks — Source | Via News | ViaNews Market